SMAD3 and neoplasm: Given that deficiency of Smad3 prevents TGF-β1-mediated inhibition of E4BP4 expression, targeting the TGF-β1/Smad3–E4BP4 axis to accelerate the development of NK cells may enhance their anticancer immunity within the tumour microenvironment.